Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 6/20 | 0.40 |
| ▸ | NOX1 | Q9Y5S8 | 6/20 | 0.40 |
| ▸ | ACHE | P22303 | 3/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9508099 | 0.85 | AHR (0.37) | — | |
| SCHEMBL9329477 | 0.82 | — | — | |
| SCHEMBL14247841 | 0.79 | CYP2A6 (0.42) | BCHENOX1ACHEMAOAGAA | |
| SCHEMBL9507748 | 0.79 | MAPK1 (0.40) | MAPTTDP1MEN1KMT2ACYP1A2 | |
| Thianthrene SCHEMBL7786 | 0.78 | BCHE (0.56) | BCHENOX1ACHEMAOAGAA | |
| Thianthrene SCHEMBL29392368 | 0.78 | BCHE (0.56) | BCHENOX1ACHEMAOAGAA | |
| SCHEMBL25643861 | 0.78 | BCHE (0.56) | BCHENOX1ACHEMAOAGAA | |
| SCHEMBL21629348 | 0.78 | BCHE (0.56) | BCHENOX1ACHEMAOAGAA | |
| SCHEMBL30823 | 0.78 | — | — | |
| Thianthrene SCHEMBL14247824 | 0.75 | BCHE (0.53) | BCHENOX1ACHEMAOAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028676-A1 | Molecular Actuators, and Methods of Use Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2011-02-03 | — | — | US | disclosed |
| US-20110028676-A1 | Molecular Actuators, and Methods of Use Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2011-02-03 | — | — | US | disclosed |
| US-20110028676-A1 | Molecular Actuators, and Methods of Use Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2011-02-03 | — | — | US | disclosed |
| US-7658868-B2 | Class of molecular actuators where bulk actuation mechanisms such as ion intercalation are enhanced by controllable single molecule conformational rearrangements offers promise in exhibiting large active strains at moderate stresses | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-02-09 | — | — | US | disclosed |
| US-7658868-B2 | Class of molecular actuators where bulk actuation mechanisms such as ion intercalation are enhanced by controllable single molecule conformational rearrangements offers promise in exhibiting large active strains at moderate stresses | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-02-09 | — | — | US | disclosed |
| US-7658868-B2 | Class of molecular actuators where bulk actuation mechanisms such as ion intercalation are enhanced by controllable single molecule conformational rearrangements offers promise in exhibiting large active strains at moderate stresses | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-02-09 | — | — | US | disclosed |
| US-20070215839-A1 | Molecular actuators, and methods of use thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070215839-A1 | Molecular actuators, and methods of use thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070215839-A1 | Molecular actuators, and methods of use thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-09-20 | — | — | US | disclosed |
| US-7138075-B2 | Molecular actuators, and methods of use thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2006-11-21 | — | — | US | disclosed |
| US-20040007695-A1 | Molecular actuators, and methods of use thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2004-01-15 | — | — | US | disclosed |
| WO-2003101955-A2 | MOLECULAR ACTUATORS, AND METHODS OF USE THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070215839-A1 | Molecular actuators, and methods of use thereof | NOD2, PIEZO1, TPR | BCHE 4471/4885NOX1 3248/4885ACHE 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.